Home » Stocks » PASG

Passage Bio, Inc. (PASG)

Stock Price: $15.88 USD -1.32 (-7.67%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 857.16M
Revenue (ttm) n/a
Net Income (ttm) -112.23M
Shares Out 53.98M
EPS (ttm) -2.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $15.88
Previous Close $17.20
Change ($) -1.32
Change (%) -7.67%
Day's Open 17.18
Day's Range 15.55 - 17.51
Day's Volume 312,031
52-Week Range 12.10 - 38.23

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

- Krabbe disease, a rare lysosomal storage disorder, has no approved disease-modifying treatment options

1 week ago - GlobeNewsWire

Passage Bio (PASG) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

2 weeks ago - Zacks Investment Research

– PBGM01 advancement to clinical development represents key milestone for Passage Bio as a clinical-stage company –

2 weeks ago - GlobeNewsWire

PHILADELPHIA, March 25, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system d...

3 weeks ago - GlobeNewsWire

PHILADELPHIA, March 22, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (C...

3 weeks ago - GlobeNewsWire

FDA designation will facilitate development and expedited review of company's lead gene therapy product candidates for life-threatening diseases with unmet medical needs: PBGM01 for GM1 gangliosidosis (...

1 month ago - GlobeNewsWire

- On track to initiate three Phase 1/2 clinical programs in the first half of 2021: PBGM01 for GM1 gangliosidosis (GM1), PBFT02 for frontotemporal dementia with granulin mutations, and PBKR03 for Krabbe...

1 month ago - GlobeNewsWire

PHILADELPHIA, March 02, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system d...

1 month ago - GlobeNewsWire

PHILADELPHIA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system di...

1 month ago - GlobeNewsWire

PHILADELPHIA, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (C...

1 month ago - GlobeNewsWire

- Phase 1/2 trial expected to commence in first half of 2021

2 months ago - GlobeNewsWire

Passage Bio Inc (NASDAQ: PASG) is leveraging the UPenn Gene Therapy Program to access compelling translational research and develop a range of differentiated adeno-associated virus gene therapies for ra...

2 months ago - Benzinga

– Second Product Candidate Expected to Enter Clinic in First Half of 2021

2 months ago - GlobeNewsWire

A secondary offering will dilute shareholders.

2 months ago - The Motley Fool

PHILADELPHIA, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system dis...

2 months ago - GlobeNewsWire

PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system dis...

2 months ago - GlobeNewsWire

MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice President, and M...

Other stocks mentioned: PHAT
3 months ago - Business Wire

PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system di...

3 months ago - GlobeNewsWire

FDA clearance marks second regulatory authorization for global Phase 1/2 clinical trial, Imagine-1 study,  expected to dose first patient in first quarter 2021

3 months ago - GlobeNewsWire

- Company invests to build in-house capabilities to support advancement of pipeline -

4 months ago - GlobeNewsWire

- MHRA approval represents first clinical trial authorization for the global PBGM01 clinical trial program -

4 months ago - GlobeNewsWire

- Completion of dedicated CGMP suite enhances manufacturing readiness and secures supply chain control to support lead CNS gene therapy product candidates as they advance through clinical trials to comm...

4 months ago - GlobeNewsWire

PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system di...

4 months ago - GlobeNewsWire

Through its unique collaboration agreement, Passage Bio has certain rights to technology highlighted in the University's research, which has the potential to significantly advance nascent field of gene ...

5 months ago - GlobeNewsWire

PHILADELPHIA, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system di...

5 months ago - GlobeNewsWire

Passage Bio, Inc. (PASG) CEO Karl Bruce Goldsmith on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

– Dosing for first patient in PBGM01 Phase 1/2 trial anticipated in 1Q2021; initial safety and biomarker data expected mid-year 2021 – – Phase 1/2 clinical trials for FTD-GRN and Krabbe expected to init...

5 months ago - GlobeNewsWire

Genetic testing, educational materials and counseling offered at no charge to patients Genetic testing, educational materials and counseling offered at no charge to patients

5 months ago - GlobeNewsWire

PHILADELPHIA, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system di...

5 months ago - GlobeNewsWire

PHILADELPHIA, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system di...

5 months ago - GlobeNewsWire

PHILADELPHIA, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system di...

5 months ago - GlobeNewsWire

Passage Bio (PASG) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

About PASG

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase (ß-gal) for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin, or PGRN, for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAV... [Read more...]

Industry
Biotechnology
IPO Date
Feb 28, 2020
Stock Exchange
NASDAQ
Ticker Symbol
PASG
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Passage Bio stock is "Strong Buy." The 12-month stock price forecast is 30.80, which is an increase of 93.95% from the latest price.

Price Target
$30.80
(93.95% upside)
Analyst Consensus: Strong Buy